1. Home >
  2. M&A >
  3. Divestiture >
  4. Belgium >
  5. Merus Labs International Acquires UCB - Three Cardiovascular Products

M&A Deal Summary

Merus Labs International Acquires UCB - Three Cardiovascular Products

On February 1, 2016, Merus Labs International acquired medical products company UCB - Three Cardiovascular Products from UCB for 92M EUR

Acquisition Highlights
  • This is Merus Labs International’s 1st transaction in the Medical Products sector.
  • This is Merus Labs International’s 0th largest (disclosed) transaction.
  • This is Merus Labs International’s 1st transaction in Belgium.

M&A Deal Summary
Date 2016-02-01
Target UCB - Three Cardiovascular Products
Sector Medical Products
Buyer(s) Merus Labs International
Sellers(s) UCB
Deal Type Divestiture
Deal Value 92M EUR

Target

UCB - Three Cardiovascular Products

Belgium
UCB - Three Cardiovascular Products consists of Elantan®, Isoket® and Deponit® rights is a producer of medical products to treat both acute and chronic coronary artery disease.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Merus Labs International

Toronto, Ontario, Canada
Category Company
Sector Life Science
Employees10
Revenue 36M USD (2015)
DESCRIPTION

Merus Labs International, Inc. is a specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. The Company leverages its expertise and scalable platform across Europe, Canada and select other markets to deliver value.

DEAL STATS #
Overall 1 of 2
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 2
Country: Belgium M&A 1 of 1
Year: 2016 M&A 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-07 Sanofi - Surgestone Provames Tredemine and Speciafoldine Rights

France

Sanofi - Surgestone, Provames, Tredemine and Speciafoldine Rights is a provider of pharmaceutical services.

Buy -

Seller(S) 1

SELLER

UCB

Brussels, Belgium
Category Company
Founded 1928
Sector Life Science
Employees9,000
Revenue 6.2B EUR (2024)
DESCRIPTION

UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.

DEAL STATS #
Overall 5 of 7
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 4 of 6
Country: Belgium M&A 3 of 3
Year: 2016 M&A 1 of 2
Size (of disclosed) 3 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-27 Kremers Urban Pharmaceuticals

Princeton, New Jersey, United States

Kremers Urban Pharmaceuticals, Inc. is a specialty generic pharmaceuticals company.

Sell $1.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-04 International Medication Systems

Berkshire, United Kingdom

International Medication Systems (UK) Ltd. is pharmaceutical company provides generic and proprietary injectable, inhalation, and intranasal products.

Sell $8M
Mergr

Solution for

Product

Company

Legal